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SUMMARY 71 
Background: Overweight and obesity are increasing worldwide. To help assess their relevance to 72 
mortality in different populations we conducted individual-participant-data meta-analyses of the 73 
prospective studies of body mass index (BMI), limiting confounding and reverse causality by 74 
restricting analyses to never-smokers and excluding prior disease and the first 5 years of follow-75 
up.  76 
Methods: Of 10,625,411 participants in Asia, Australia/New Zealand, Europe, and North America 77 
from 239 prospective studies (median follow-up 13·7 [IQR: 11·4-14·7] years), 3,951,455 in 189 78 
studies were never-smokers without specific chronic diseases at recruitment who survived 5 years, 79 
of whom 385,879 died. The primary analyses are of these deaths, using age and sex-adjusted 80 
hazard ratios (HRs). 81 
Findings: All-cause mortality was minimal (HR=1) at BMI (kg/m2) 20-25, and increased 82 
significantly both just below this range (BMI 18·5-<20: HR=1·13, 95%CI 1·09-1·17; BMI 15-83 
<18·5: HR=1·51, 1·43-1·59) and throughout the overweight range just above it (BMI 25-<27·5: 84 
HR=1·07, 1·07-1·08; BMI 27·5-<30: HR=1·20, 1·18-1·22). Continuing upwards, HRs for obesity 85 
grade I, II, and III (BMI 30-<35, 35-<40, 40-<60) were 1·45 (1·41-1·48), 1·94 (1·87-2.01), and 86 
2·76 (2·60-2·92), respectively. For BMI>25, mortality increased approximately log-linearly with 87 
BMI; HR per 5 units higher BMI was 1·31 (1·29-1·33) in all regions; 1·39 (1·35-1·43) in Europe; 88 
1·29 (1·26-1·32) in North America, 1·39 (1·34-1·44) in East Asia, and 1.31 (1.27, 1.35) in 89 
Australia/New Zealand. This HR per 5 units higher BMI (for BMI>25) was greater in younger than 90 
older people (1.52 at 35–49 years vs 1·21 at 70-89 years; Pheterogeneity<0·0001), greater in men 91 
than women (1·51 vs 1·30; Pheterogeneity<0·0001), but similar in studies with self-reported and  92 
measured BMI. 93 
Interpretation: The associations of both overweight and obesity with higher all-cause mortality 94 
were broadly consistent in four continents. This supports strategies to combat the entire spectrum 95 
of excess adiposity in many populations. 96 
Funding: UK MRC, BHF, NIHR; US NIH   97 
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INTRODUCTION 98 
 99 
The worldwide prevalence of overweight and obesity is high and increasing.1 The World Health 100 
Organization (WHO) estimates that more than 1·3 billion adults worldwide are overweight (defined 101 
by WHO as a body mass index [BMI weight in kg/the square of height in m] of 25-<30 kg/m2), and 102 
a further 600 million are obese (BMI ≥30 kg/m2).2 Analyses of large-scale prospective studies with 103 
prolonged follow-up generally indicate that both overweight and obesity are associated with 104 
increased mortality, as is underweight (defined conservatively by the WHO as BMI <18.5 kg/m2). 105 
However, it is not known how such associations vary across major global regions, an uncertainty 106 
relevant to international strategies on overweight and obesity.3 Most previous analyses have 107 
focused on people living in one particular country or continent,4-11 even though relationships of 108 
overweight and underweight might differ from one population to another.  109 
 110 
Estimation of the relationships between BMI and mortality in various populations can help assess 111 
the adverse physiological effects of excessive adiposity (and the adverse physiological effects of 112 
various determinants of low BMI). However, reliable estimates of the relevance of BMI to mortality 113 
need to limit the effects of reverse causality, because chronic disease and smoking can themselves 114 
affect BMI. To help achieve more valid estimates, prospective studies of BMI and mortality should 115 
where possible exclude smokers, exclude participants who already had some chronic disease at 116 
recruitment that could affect BMI, and those dying within 5 years of recruitment. 12-15 117 
 118 
The Global BMI Mortality Collaboration was established to provide a standardised comparison of 119 
associations of BMI with mortality across different populations. It includes individual-participant 120 
data on 10·6 million adults in 239 prospective cohort studies in 32 countries, mainly located in 121 
Australia/New Zealand (NZ), East Asia, Europe, or North America, about 4 million of whom were 122 
non-smokers without chronic disease at recruitment who were still being followed up 5 years 123 
afterwards. 124 
125 
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METHODS 126 
In 2013, over 500 investigators (eAppendix 1) from over 300 institutions in 32 countries agreed 127 
an analysis plan for combining individual-participant data from contributing studies. This pre-128 
specified analysis plan is provided in eAppendix 2. The goal was to produce reliable estimates of 129 
associations of overweight and obesity with all-cause mortality using data from studies in several 130 
regions. The pre-specified analysis methods were designed to maximize the internal validity by 131 
reducing the scope for bias. This paper follows PRISMA-IPD reporting guidelines (eAppendix 3).16  132 
 133 
Data Sources 134 
We sought data from large prospective studies (≥100,000 participants at baseline) or large multi-135 
cohort consortia (total ≥100,000 participants at baseline). We identified studies from 1970 to 136 
January 2015 through systematic literature searches and discussion with investigators (eAppendix 137 
4). Prospective cohort studies or consortia thereof were eligible if they: 1) had information on 138 
weight, height, age and sex; 2) did not select participants on the basis of having previous chronic 139 
disease; 3) recorded overall or cause-specific deaths; and 4) had accrued ≥5 years of median 140 
follow-up. We identified only two eligible studies that were unable to contribute (eFigure 1).17,18 141 
eTables 1-2 provide details of studies. The contributing studies classified deaths according to the 142 
primary cause (or, in its absence, the underlying cause), on the basis of coding from the 143 
International Classification of Diseases, revisions 8 through 10, to at least three digits (eTable 3), 144 
or according to study-specific classification systems. Ascertainment of outcomes was based on 145 
death certificates, supplemented in some studies by additional data.  146 
 147 
Statistical methods 148 
eFigure 1 describes inclusion and exclusion criteria. We excluded participants with a BMI <15 or 149 
≥60kg/m2, or baseline age <20 or ≥90 years. To limit residual confounding by smoking and bias 150 
due to effects of pre-existing disease on baseline BMI (i.e., reverse causality), the primary analysis 151 
was restricted to never-smokers without certain known chronic diseases at baseline (e.g., 152 
cardiovascular disease, cancer, or respiratory diseases), and omitted the first 5 years of follow-up.  153 
 154 
Associations of all-cause mortality with BMI depend not only on the associations of specific causes 155 
of death with BMI in different regions (which might differ quantitatively), but also on how relatively 156 
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common each specific cause of death is in the particular region (which can differ substantially by 157 
region and over time). Hence, the association of all-cause mortality with BMI may differ in regions 158 
with different underlying mortality patterns. Therefore, the pre-specified primary analysis was 159 
stratified by 5 major geographical regions, 3 with extensive data (East Asia, Europe, North 160 
America) and 2 with more limited data (Australia/NZ and South Asia). Data from some or all 161 
regions are shown separately, in the main text or the extensive online Supplementary Analyses. 162 
 163 
Each study (or consortium of studies) analysed individual-participant data according to a common 164 
analytical plan (SASv9·3 [SAS Institute, Cary, NC] or  Statav12 [StataCorp, College Station, TX]) 165 
provided by the coordinating centres. These separate results were then meta-analysed at 166 
Cambridge University, UK. To facilitate standardised comparisons with other meta-analyses, we 167 
calculated hazard ratios (HRs) for mortality in the 6 WHO-defined baseline BMI categories: 168 
underweight (15·0-<18·5 kg/m2), normal (18·5-<25 kg/m2, the reference category for  analyses of 169 
6 BMI groups), overweight (25-<30 kg/m2), and obesity grades I (30-<35 kg/m2), II (35-<40 170 
kg/m2), and III (40-<60 kg/m2).19 As, however, most people are of normal weight or overweight, 171 
these two categories were subdivided, yielding 9 fine groups: 15·0-<18·5, 18·5-<20, 20-<22·5, 172 
22·5-<25·0 (the reference category for analyses of 9 BMI groups), 25·0-<27·5, 27·5-<30, 30-173 
<35·0, 35·0-<40, and 40-<60 kg/m2. 174 
 175 
Study-specific log HRs in particular BMI categories were pooled by inverse-variance-weighted 176 
random-effects meta-analyses (an extension of the DerSimonian and Laird procedure) and plotted 177 
against mean BMI value within each category. To make comparisons across BMI groups 178 
irrespective of the choice of a reference group, a floating variance estimate (reflecting independent 179 
variability within each group, including the reference group) was attributed to each category using 180 
Plummer’s method and used to calculate group-specific confidence intervals (CIs).20  181 
 182 
To estimate BMI levels at which mortality risk was lowest (i.e., the nadir), weighted linear 183 
regression yielded the best-fitting second-degree fractional polynomial model relating pooled log 184 
HRs to pooled mean BMI levels (weighted by the inverse of the floating variance of the log HR), 185 
and the minimum of this polynomial was the nadir.  186 
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 187 
We assessed all-cause mortality and its main components, coronary heart disease, stroke, 188 
cardiovascular disease, cancer, and respiratory disease (eTable 3). HRs were calculated separately 189 
within each study using Cox regression models stratified for age and sex (eAppendix 2). Attained 190 
age was used, with participants contributing from the baseline survey in crude analyses or from 191 
year 5 in the primary analyses. HRs in sex- and age-specific groups (and, where appropriate, by 192 
trial arms) were combined across studies.21 To avoid over-fitting of statistical models, studies with 193 
≤10 deaths from a particular cause were excluded from meta-analyses of that cause.22,23  194 
 195 
Because BMI-mortality associations were approximately log-linear above a BMI of 25 kg/m2, we 196 
calculated HRs per 5 kg/m2 increase by inverse-variance-weighted regression of the pooled log HRs 197 
on mean BMI values in each category.16 For all-cause mortality we estimate population-attributable 198 
fractions (PAFs) for underweight, overweight and obese by combining the proportional excess 199 
mortality versus normal weight (HR-1) in these BMI categories (X0, X1 and X2 respectively) with 200 
the corresponding prevalences (P0, P1 and P2, taken from Global Burden of Disease
24 region-specific 201 
prevalences). The PAFs for overweight and obesity are then P1X1/k and P2X2/k, where 202 
k=1+P0X0+P1X1+P2X2. Between-study heterogeneity was quantified by the I
2 statistic.25 We used 2-203 
sided P-values and 95% CIs.  204 
 205 
Role of funders 206 
No sponsor had any role in study design, conduct analysis or interpretation; in manuscript 207 
preparation, review, or approval; or in deciding to submit for publication.  208 
  209 
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RESULTS 210 
Of 10,625,411 participants from 239 studies (median follow-up 13·7 [IQR 11·4-14·7] years), 211 
3,951,455 were never-smokers without specific chronic diseases at recruitment who survived 5 212 
years, of whom 385,879 died. To limit bias, the pre-specified primary analyses involve this 213 
restricted population. To avoid merging importantly different risks, many of these primary analyses 214 
further subdivide the WHO-defined normal and overweight BMI categories, yielding 9 BMI groups 215 
rather than 6.  216 
 217 
Table 1 shows the substantial relevance of successively stricter exclusions, going from crude 218 
analyses of 10·6 million to pre-specified analyses of 4 million adults. With BMI in only 6 groups the 219 
whole range from 18.5 to <25 kg/m2 is the reference group, and HRs were: underweight 1·47 220 
(95% CI 1·39-1·55), overweight 1·11 (1·10-1·11), and grade I, II, III obesity 1·44 (1·41-1·47), 221 
1·92 (1·86-1·98), and 2·71 (2·55-2·86), respectively. With normal and overweight more finely 222 
subdivided, however, BMI 22·5-<25 becomes the reference group, and mortality was minimal at 223 
BMI 20-<25, and was significantly increased just below this range (BMI 18·5-<20: 1·13, 1·09-224 
1·17; 15-<18·5: 1·51, 1·43-1·59) and throughout the overweight range just above it (BMI 25-225 
<27·5: HR=1·07, 1·07-1·08; BMI 27·5-<30: HR=1·20, 1·18-1·22). With this more precise 226 
reference group, the HRs for grade I, II, III obesity increased to 1·45 (1·41-1·48), 1·94 (1·87-227 
2.01), and 2·76 (2·60-2·92).  228 
 229 
In these pre-specified analyses of 4 million adults, the HRs for overweight and for obesity grade I 230 
were broadly similar across different geographic regions (Europe, North America, East Asia, and 231 
Australia/NZ; numbers of deaths in South Asia were too small to be reliable), but the HRs for 232 
underweight and grade III obesity appeared somewhat higher in Europe than in East Asia (Figure 233 
1, Table 2, eTables 4-9).  234 
 235 
Combining all regions, the HRs for overweight and obesity were higher in men than women, and 236 
higher at younger than older ages (Figures 2-3); this held in each major geographic region 237 
(eFigures 2-4, eTables 10-11). In each region, BMI was non-linearly associated with all-cause 238 
mortality, with nadir at BMI 20-<25 and excess mortality in underweight, overweight, and at BMI 239 
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18.5-<20, at the lower end of the WHO-defined normal range. The nadir depended on age: it was 240 
BMI=22 for age 35-49 years, BMI=23 for 50-69 years, and BMI=24 for 70-89 years).  241 
 242 
Population-attributable fractions for all-cause mortality due to overweight or obesity were 18% 243 
North America, 15% Europe, 10% Australia/NZ, but only 5% East Asia (eTable 12). For BMI≥25, 244 
the association of BMI with all-cause mortality was approximately log-linear, and of similar 245 
strength in each region (except perhaps South Asia, where numbers were limited), with HR per 5 246 
units higher BMI 1·31 (1·29-1·33) overall, 1·39 (1·34-1·44) in East Asia, 1·39 (1·34-1·43) in 247 
Europe, 1·29 (1·26-1·32) in North America, and 1.31 (1.27, 1.35) in Australia/NZ. It was 1·51 248 
(1.46-1.56) for men as against only 1·30 (1.26-1.33) for women, heterogeneity P<0·0001, and it 249 
decreased with age from 1·52 (1·47-1·56) for ages 35–49 years at baseline to 1·21 (1·17-1·25) for 250 
ages 70-89 years, trend P<0·0001 (eTable 13).  251 
 252 
For each major cause of death, BMI was non-linearly associated with mortality in each major 253 
region we studied (Figure 4, eFigure 5, eTables 14-15). Above 25 kg/m2, it was strongly 254 
positively related to coronary, stroke and respiratory mortality, and moderately related to cancer 255 
mortality. Findings for overweight and obesity were broadly similar in Europe, North America and 256 
East Asia. Within the WHO’s wide normal BMI range (18.5-<25 kg/m2) the main geographic 257 
difference was that in East Asia mortality from coronary heart disease was steeply lower with 258 
decreasing BMI (having nadir at 18.5-<20 kg/m2), but in other regions it was not (eTable 15). In 259 
all regions, underweight was associated with substantially higher respiratory mortality and 260 
somewhat higher mortality from coronary heart disease, stroke, and cancer. HRs comparing 261 
underweight versus normal weight cardiovascular mortality were more extreme in Europe than 262 
elsewhere.  263 
 264 
Compared with the strict primary analyses noted above, crude analyses that ignored smoking, 265 
ignored any effects of prior disease at baseline and failed to exclude the first 5 years of follow-up 266 
yielded different (presumably substantially biased) results, with exaggerated HRs for underweight, 267 
no apparent HRs for overweight and less than half of the less-biased HRs for grade I obesity 268 
(Table 1, eFigure 6). In sensitivity analyses (eFigures 7-11, eTables 17-23), HRs were little 269 
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changed in analyses that: used fixed effect models or restricted follow-up to years 5-15; 270 
considered age at risk rather than age at baseline; used contemporary mortality rates; adjusted 271 
additionally for race or excluded participants with diabetes at baseline; used only studies that 272 
included both sexes; used only studies with baseline data on heart disease, stroke and cancer; or 273 
subdivided studies by mean baseline BMI or median recruitment year (HRs were somewhat higher 274 
in studies starting before than since 1990, but meta-regression of HRs on year of recruitment was 275 
not significant). HRs did not vary substantially between larger and smaller studies, between studies 276 
with measured and self-reported BMI, or between occupational and other studies. 277 
 278 
DISCUSSION 279 
Associations between BMI and mortality can help estimate the public health impact of excess 280 
adiposity only if the estimated relationships are not substantially distorted by the effects of 281 
smoking or ill health on BMI. Hence, our primary analyses were of non-smokers without prior 282 
disease who survived at least 5 years. We conducted standardised comparison of associations of 283 
BMI with mortality across prospective studies in four continents. Both overweight and obesity were 284 
associated with all-cause mortality. In the BMI range above 25 kg/m2 (the upper limit of the WHO’s 285 
normal range) the relationship to mortality was steep in every global region we studied, except 286 
perhaps South Asia where numbers were small.26  287 
 288 
Our primary analyses challenge previous suggestions that overweight (25-<30) and grade I 289 
obesity (30-<35) are not associated with higher mortality,27 bypassing speculation about 290 
hypothetical protective metabolic effects of increased body fat in apparently healthy individuals.28 291 
In particular, the findings here contrast with those of a recent review of published data which 292 
found that, relative to normal weight, grade I obesity was not associated with higher mortality and 293 
overweight was associated with lower all-cause mortality.27 That review could not, however, 294 
control for the biases controlled for in the current analysis. Indeed, the results of the current 295 
analysis (eg, Table 1 and eTables 4-5) show how that literature-based review’s limited ability to 296 
control for bias could have accounted for its misleading findings. Our study was able to reproduce 297 
such findings when conducting crude analyses with inadequate control of reverse causality, but not 298 
when we conducted appropriately strict analyses. 299 
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Despite broadly similar overall findings across different continents, we found some differences. HRs 300 
per 5-unit increment of BMI above 25 kg/m² were higher in Europe than in North America. HRs 301 
were higher in males than females, consistent with previous observations that, at  equivalent BMI 302 
levels, men have greater insulin resistance, ectopic (e.g., liver) fat levels and type 2 diabetes 303 
prevalence.29 In each major region we studied, HRs were substantially higher at younger than at 304 
older ages, although the absolute excess mortality rate was higher in older people.  305 
 306 
Partly because the prevalence of obesity differs by region, for all-cause mortality there was wide 307 
variation across regions in the approximate population-attributable fraction due to overweight and 308 
obesity: North America 18%, Europe 15%, Australia/New Zealand 10%, and East Asia 5%. These 309 
findings suggest that if the entire population had ideal levels of BMI this would avoid about 1 in 5 310 
premature deaths in North America, 1 in 7 in Europe,1 in 10 in Australia/New Zealand, and 1 in 20 311 
in East Asia, assuming that the associations of overweight and obesity with mortality in our 312 
primary analyses largely reflect causal effects. Instead, however, BMI is increasing in many 313 
populations, so the pattern of high mortality from adiposity in North America may become typical 314 
elsewhere unless this increase in overweight and obesity can be halted.30 At the opposite extreme, 315 
there was a substantially higher mortality rate not only among those in WHO’s underweight 316 
category, but also in those with BMI 18.5-<20 kg/m2, suggesting that in excessively lean 317 
populations underweight remains a cause for concern. We have no information on whether the BMI 318 
in underweight individuals was always low. 319 
 320 
Our primary analyses used three main approaches to help avoid bias. First, we restricted analysis 321 
to never-smokers to avoid as fully as possible residual confounding by smoking because merely 322 
adjusting for smoking habits would be unlikely to eliminate important residual biases due to the 323 
effect on BMI of different intensity of smoking.12 Second, we excluded people known to have 324 
certain pre-existing chronic diseases (although full information on this was often unavailable). 325 
Finally, we omitted the initial five years of follow-up from the analysis because conditions at 326 
baseline that might cause death over the next 5 years, could result in reverse causation (where 327 
lower BMI at recruitment is the result, rather than the cause, of the underlying pathology).13-15  328 
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Our findings are consistent with other (albeit less precise) studies that have used effective 329 
methods to reduce potential bias in evaluations of a causal relationship between excess BMI and 330 
mortality, such as Mendelian randomisation analyses,31,32 other instrumental variable analyses,33 331 
and a meta-analysis of randomised trials.34 Our findings are also broadly consistent with the 332 
stricter analyses done in a recent study of 12 million Korean adults.35  333 
 334 
The most important limitation is that our only measure of adiposity was BMI, so we could not 335 
address aspects of body composition such as visceral fat or fat distribution,36,37 nor could we 336 
consider modification of HRs by metabolic factors.38 Such factors may have different effects in 337 
different populations as, given the same BMI, people of Asian ancestry may have higher amounts 338 
of body fat and greater risk of developing metabolic diseases than people of European ancestry.39 339 
Moreover, South Asia, Africa, and Latin America were either unrepresented or poorly represented, 340 
and large studies in those areas might yield somewhat different findings. The study-specific results 341 
were in general not adjusted for ethnicity, or for socioeconomic status. We did not adjust for 342 
regression dilution because previous surveys have reported high levels of concordance in replicate 343 
BMI measures taken from the same adults some years apart.40  344 
 345 
There are, however, particular strengths. Compared with single-country studies, we enhanced 346 
generalisability by combining findings from 239 studies across four continents. We had access to 347 
data for about 97% of the participants in the studies eligible for this analysis (giving large numbers 348 
and negligible bias from unavailability of particular studies), we used a pre-specified analysis plan, 349 
we analysed individual-participant data to avoid the potentially important limitations of literature-350 
based reviews,41 we analysed clinically relevant subpopulations reliably, exploiting the considerable 351 
statistical power of the study. We avoided potential “over-adjustment” by not adjusting for 352 
variables (e.g, diabetes status, physical activity) that could mediate associations between BMI and 353 
mortality.42 Finally, our results were robust to a variety of sensitivity analyses. 354 
 355 
We conclude that wherever overweight and obesity are common their associations with higher all-356 
cause mortality are positive and broadly similar, supporting strategies to combat the entire 357 
spectrum of excessive adiposity worldwide.  358 
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Table 1: Effects of successively stricter precautions against bias on analyses of BMI vs all-cause mortality  476 
 477 
  
Underweight Normal weight Overweight Obesity Grade I Obesity Grade II Obesity Grade III 
(BMI 15 to <18·5) (18·5 to <25) (25 to <30) (30 to <35) (35 to <40) (40 to <60) 
6 WHO BMI groups: Crude analysis with no exclusions  
(237 studies; 10,622,450 participants; 1,601,774 deaths) 
Participants / deaths 292003 / 68455 5586892 / 810838 3467617 / 526098 946257 / 144871 237223 / 36113 92458 / 15399 
HR (95% CI) 1·82 (1·74, 1·91) 1·00 (0·98, 1·02) 0·95 (0·94, 0·97) 1·17 (1·16, 1·18) 1·49 (1·47, 1·51) 1·95 (1·90, 2·01) 
6 WHO BMI groups: Participants without known disease at baseline 
(236 studies; 9,104,247 participants; 1,210,250 deaths) 
Participants / deaths 255000 / 52789 4922817 / 631488 2916978 / 388781 756075 / 102315 183689 / 24556 69688 / 10321 
HR (95% CI) 1·81 (1·72, 1·91) 1·00 (0·98, 1·02) 0·95 (0·95, 0·96) 1·18 (1·16, 1·20) 1·52 (1·48, 1·55) 2·05 (1·98, 2·13) 
6 WHO BMI groups: Participants without known chronic disease at baseline, adjusting for smoking status 
(234 studies; 8,801,617 participants; 1,185,728 deaths) 
Participants / deaths 245080 / 51170 4751019 / 618881 2826687 / 381617 733108 / 100113 178130 / 23945 67593 / 10002 
HR (95% CI) 1·70 (1·61, 1·80) 1·00 (0·98, 1·02) 0·99 (0·98, 1·00) 1·25 (1·23, 1·27) 1·63 (1·59, 1·66) 2·24 (2·15, 2·33) 
6 WHO BMI groups: Participants without known chronic disease at baseline, adjusting for smoking status, and excluding the first 5 years of follow-up 
(213 studies; 7,805,434 participants; 949,010 deaths) 
Participants / deaths 208044 / 33817 4234052 / 496310 2513128 / 312450 641237 / 80037 152741 / 18737 56232 / 7659 
HR (95% CI) 1·60 (1·51, 1·70) 1·00 (0·98, 1·02) 1·03 (1·01, 1·04) 1·31 (1·29, 1·33) 1·70 (1·67, 1·74) 2·36 (2·27, 2·45) 
6 WHO BMI groups (a primary pre-specified analysis): Never-smokers without known chronic disease at baseline, excluding the first 5 years of follow-up 
(189 studies; 3,951,455 participants; 385,879 deaths) 
Participants / deaths 114091 / 12726 2145550 / 192523 1250103 / 130293 330840 / 37318 80827 / 9179 30044 / 3840 
HR (95% CI) 1·47 (1·39, 1·55) 1·00 (0·98, 1·02) 1·11 (1·10, 1·11) 1·44 (1·41, 1·47) 1·92 (1·86, 1·98) 2·71 (2·55, 2·86) 
9 BMI groups (strictest precautions against bias: a primary pre-specified analysis): As above, but with normal weight and overweight further subdivided 
(189 studies; 3,951,455 participants; 385,879 deaths) 
BMI categories 15 to <18.5 18.5 to <20 20 to <22.5 22.5 to <25 25 to <27.5 27.5 to <30 30 to <35 35 to <40 40 to <60 
Participants/deaths 114091/12726 230749/20989 838907/72701 1075894/98833 821303/84952 428800/45341 330840/37318 80827/9179 30044/3840 
HR (95% CI) 1.51 
(1.43, 1.59) 
1.13 
(1.09, 1.17) 
1.00 
(0.98, 1.02) 
1.00 
(0.99, 1.01) 
1.07 
(1.07, 1.08) 
1.20 
(1.18, 1.22) 
1.45 
(1.41, 1.48) 
1.94 
(1.87, 2.01) 
2.76 
(2.60, 2.92) 
 478 
All analyses are adjusted for age and sex  479 
 480 
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Table 2: Strictest pre-specified analyses, in geographic regions with >1 million participants: Nine BMI groups vs all-cause 481 
mortality among never-smokers, excluding chronic disease at baseline and 5 years follow-up 482 
 
483 
 484 
 BMI categories 15 to <18.5 18.5 to <20 20 to <22.5 22.5 to <25 25 to <27.5 27.5 to <30 30 to <35.0 35 to <40 40 to <60 
Europe 
(89 studies; 1,135,600 participants; 56,477 deaths)       
Participants/deaths 13398/675 42584/1508 199369/7449 306566/13278 249929/12850 153147/8935 127536/8386 32749/2424 10322/972 
HR (95% CI) 
1.79 
(1.63, 1.97) 
1.25 
(1.14, 1.38) 
1.02 
(0.97, 1.07) 
1.00 
(0.97, 1.03) 
1.07 
(1.06, 1.09) 
1.21 
(1.18, 1.25) 
1.52 
(1.45, 1.58) 
1.99 
(1.87, 2.12) 
3.04 
(2.84, 3.27) 
North America 
(40 studies; 1,415,087 participants; 219,922 deaths)       
Participants/deaths 22028/3846 67114/8597 274883/36200 359022/54995 317721/53464 168183/28471 149807/25348 39379/6299 16950/2702 
HR (95% CI) 
1.51 
(1.34, 1.70) 
1.09 
(1.02, 1.16) 
1.01 
(0.96, 1.06) 
1.00 
(0.97, 1.03) 
1.06 
(1.04, 1.07) 
1.17 
(1.12, 1.22) 
1.39 
(1.30, 1.49) 
1.93 
(1.74, 2.13) 
2.58 
(2.26, 2.93) 
East Asia 
(46 studies; 1,074,385 participants; 100,784 deaths)       
Participants/deaths 46979/7178 94409/10206 301242/27537 336758/28755 194857/17070 72133/6950 25658/2753 1941/231 408/104 
HR (95% CI) 
1.36 
(1.25, 1.49) 
1.11 
(1.04, 1.18) 
0.99 
(0.97, 1.02) 
1.00 
(0.97, 1.03) 
1.07 
(1.04, 1.11) 
1.28  
(1.21, 1.35) 
1.54 
(1.42, 1.67) 
2.01 
(1.59, 2.54) 
2.38 
(1.33, 4.24) 
          
P-value for 
heterogeneity 
0.0045 0.28 0.42 - 0.89 0.46 0.20 0.48 <0.0001 
 485 
Normal weight and overweight are subdivided, and the reference category is BMI 22·5 to <25 kg/m2.  486 
Numbers of studies, participants and deaths are after exclusions from these pre-specified principal analyses.  487 
CIs were calculated using floating variance estimates (reflecting independent variability within each group, including the reference group).  488 
Results from studies in South Asia and Australia/New Zealand are in Figure 1, with details in eTable 8 of the Supplementary Material.  489 
 490 
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Figure 1: Association of BMI with all-cause mortality, by geographical region 491 
 492 
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 493 
 494 
HR, hazard ratio per 5 kg/m
2
 unit of BMI in the range BMI >25 kg/m2 (and 95% CI).  495 
 496 
Analyses restricted to never-smokers without pre-existing chronic disease, and excluding the first 5 years of follow-up, 497 
and include data from all geographical regions. 498 
 499 
BMI groups: 15.0 to <18.5, 18.5 to <20, 20 to <22.5, 22.5 to <25.0, 25.0 to <27.5, 27.5 to <30, 30 to <35.0, 35.0 500 
to <40, and 40 to <60 kg/m
2
. Reference category (arrow) is 22.5 to <25 kg/m
2
.  501 
 502 
CIs are from floating variance estimates (reflecting independent variability within each category, including reference). 503 
Areas of squares are proportional to the information content.  504 
 505 
  506 
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Figure 2: Association of BMI with all-cause mortality, by baseline age group 507 
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 509 
HR, hazard ratio per 5 kg/m
2
 unit of BMI in the range BMI >25 kg/m2 (and 95% CI).  510 
 511 
Analyses restricted to never-smokers without pre-existing chronic disease, and excluding the first 5 years of follow-up, 512 
and include data from all geographical regions. 513 
 514 
BMI groups: 15.0 to <18.5, 18.5 to <20, 20 to <22.5, 22.5 to <25.0, 25.0 to <27.5, 27.5 to <30, 30 to <35.0, 35.0 515 
to <40, and 40 to <60 kg/m
2
. Reference category (arrow) is 22.5 to <25 kg/m
2
.  516 
 517 
CIs are from floating variance estimates (reflecting independent variability within each category, including reference). 518 
Areas of squares are proportional to the information content. 519 
 520 
Analyses by age and the 3 main geographic regions are in eFigure 2. 521 
 522 
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Figure 3: Association of BMI with all-cause mortality, by sex 523 
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 525 
HR, hazard ratio per 5 kg/m
2
 unit of BMI in the range BMI >25 kg/m2 (and 95% CI).  526 
 527 
Analyses restricted to never-smokers without pre-existing chronic disease, and excluding the first 5 years of follow-up, 528 
, and include data from all geographical regions. 529 
 530 
BMI groups: 15.0 to <18.5, 18.5 to <20, 20 to <22.5, 22.5 to <25.0, 25.0 to <27.5, 27.5 to <30, 30 to <35.0, 35.0 531 
to <40, and 40 to <60 kg/m
2
. Reference category (arrow) is 22.5 to <25 kg/m
2
.  532 
 533 
CIs are from floating variance estimates (reflecting independent variability within each category, including reference). 534 
Areas of squares are proportional to the information content.  535 
Analyses by sex and the 3 main geographic regions are in eTable 10 and eFigures 3-4. 536 
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Figure 4: Association of BMI with mortality, by major underlying cause 537 
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 539 
HR, hazard ratio per 5 kg/m
2
 unit of BMI in the range BMI >25 kg/m2 (and 95% CI). Analyses restricted to never-540 
smokers without pre-existing chronic disease, and excluding the first 5 years of follow-up, and include data from all 541 
geographical regions. 542 
 543 
BMI groups: 15.0 to <18.5, 18.5 to <20, 20 to <22.5, 22.5 to <25.0, 25.0 to <27.5, 27.5 to <30, 30 to <35.0, 35.0 544 
to <40, and 40 to <60 kg/m
2
. Reference category (arrow) is 22.5 to <25 kg/m
2
.  545 
 546 
CIs are from floating variance estimates (reflecting independent variability within each category, including reference). 547 
Areas of squares are proportional to the information content.  548 
 549 
Analyses of cause-specific mortality by 3 geographic regions are in eTable 15 and eFigure 5. 550 
